Research Highlight |
Featured
-
-
-
News & Views |
Implications of high-dose statin link with incident diabetes
According to a meta-analysis of five clinical trials, high-dose statin therapy is associated with increased risk of new-onset diabetes mellitus. When treating patients with excessive levels of non-HDL cholesterols despite moderate-dose statin therapy, should we prescribe a strategy known to be efficacious, but associated with safety concerns, or should we prescribe combination therapy that has no proven effects on outcomes?
- Michael H. Davidson
-
News & Views |
Clopidogrel–PPI interaction, an ongoing controversy
Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPIs), whether its clinical efficacy is reduced remains highly controversial. The FDA and European Medicines Agency recommend that PPIs and clopidogrel should not routinely be coadministered, and the 2010 expert consensus guidelines support this recommendation.
- Paul A. Gurbel
- & Udaya S. Tantry
-
-
Review Article |
New developments in atrial antiarrhythmic drug therapy
Atrial fibrillation (AF) has multifactorial intracardiac and extracardiac causes. Current development of anti-AF agents is focused on modulation of ion channel activity as well as on upstream therapies that reduce structural substrates. In this Review, Burashnikov and Antzelevitch examine new and emerging pharmacological approaches to rhythm control in patients with AF and summarize the available data on these drugs.
- Alexander Burashnikov
- & Charles Antzelevitch
Beneficial effects of evacetrapib
Making the SWAP from clopidrogrel to prasugrel